AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair

Oncotarget
James B FordChristopher C Porter

Abstract

While some children with acute lymphoblastic leukemia (ALL) have excellent prognoses, the prognosis for adults and children with T cell ALL is more guarded. Treatment for T-ALL is heavily dependent upon antimetabolite chemotherapeutics, including cytarabine. Targeted inhibition of WEE1 with AZD1775 has emerged as a strategy to sensitize cancer cells to cytarabine and other chemotherapeutics. We sought to determine if this strategy would be effective for T-ALL with clinically relevant anti-leukemia agents. We found that AZD1775 sensitizes T-ALL cells to several traditional anti-leukemia agents, acting synergistically with cytarabine by enhancing DNA damage and apoptosis. In addition to increased phosphorylation of H2AX at serine 139 (γH2AX), AZD1775 led to increased phosphorylation of H2AX at tyrosine 142, a signaling event associated with promotion of apoptosis over DNA repair. In a xenograft model of T-ALL, the addition of AZD1775 to cytarabine slowed leukemia progression and prolonged survival. Inhibition of WEE1 with AZD1775 sensitizes T-ALL to several anti-leukemia agents, particularly cytarabine and that mechanistically, AZD1775 promotes apoptosis over DNA repair in cells treated with cytarabine. These data support the dev...Continue Reading

References

Oct 1, 1990·Antiviral Research·M N Prichard, C Shipman
Sep 27, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John M GoldbergBarbara L Asselin
Jul 12, 2005·Pediatric Blood & Cancer·Stuart S WinterMichael D Amylon
Apr 19, 2008·Nature Reviews. Immunology·Iannis AifantisSilvia Buonamici
Oct 29, 2008·Oncogene·B EwaldW Plunkett
Feb 24, 2009·Nature·Peter J CookMichael G Rosenfeld
Jan 14, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yun Dai, Steven Grant
Mar 14, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen P HungerWilliam L Carroll
Oct 2, 2012·The Journal of Clinical Investigation·Pieter Van Vlierberghe, Adolfo Ferrando
Oct 25, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judith E KarpScott H Kaufmann
Jun 26, 2014·Pediatric Blood & Cancer·J Timothy CaldwellJeffrey W Taub

❮ Previous
Next ❯

Citations

Nov 11, 2019·Cancers·Mathilde Rikje Willemijn de JongTom van Meerten
Sep 23, 2020·Journal of Hematology & Oncology·Andrea Ghelli Luserna di RoràGiorgia Simonetti
Aug 3, 2018·Journal of Hematology & Oncology·Andrea Ghelli Luserna Di RoràGiovanni Martinelli
Aug 14, 2018·Expert Opinion on Investigational Drugs·Siqing FuFunda Meric-Bernstein
Mar 31, 2017·Journal of Hematology & Oncology·A Ghelli Luserna di Rora'G Martinelli
Nov 4, 2017·Cancer Research·Christopher C MillsValerie B Sampson
Aug 15, 2021·DNA Repair·Sajjad Vakili-SamianiFarhad Jadidi-Niaragh

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry

Software Mentioned

MacSynergy
Graphpad Prism
CalcuSyn
Excel

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

© 2021 Meta ULC. All rights reserved